Target family: IKK family (type: enzyme)
Target: TANK binding kinase 1

Ligand: TBK1 PROTAC 3i (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.890000343322754 pKd
Reference (Journal): Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.
Published in: J Med Chem

Ligand: SR8185 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8 pIC50
Reference (Journal): Selective TBK1/IKKi dual inhibitors with anticancer potency.
Published in: Int J Cancer

Ligand: MRT67307 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.71999979019165 pIC50
Reference (Journal): Novel cross-talk within the IKK family controls innate immunity.
Published in: Biochem J

Ligand: MPI-0485520 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.699999809265137 pIC50
Reference (Patent): Pyrimidine compounds as inhibitors of protein kinases ikk epsilon and/or tbk-1, processes for their preparation, and pharmaceutical compositions containing them

Ligand: GSK8612 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8 pKd
Reference (Journal): Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor.
Published in: ACS Med Chem Lett

Ligand: compound II [PMID: 21329883] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.889999866485596 pIC50
Reference (Journal): TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation.
Published in: Mol Cell

Ligand: compound 6 [PMID: 34333981] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.179999828338623 pIC50
Reference (Journal): Identification of Pyrimidine-Based Lead Compounds for Understudied Kinases Implicated in Driving Neurodegeneration.
Published in: J Med Chem

Ligand: BX-795 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.220000267028809 pIC50
Reference (Journal): Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation.
Published in: J Biol Chem

Ligand: BAY-985 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor.
Published in: J Med Chem

Ligand: AZ13102909 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.300000190734863 pIC50
Reference (Journal): Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.
Published in: Mol Cancer Res

Ligand: amlexanox (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1996)
Primary target: no
Median affinity:  pIC50
Reference (Journal): An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice.
Published in: Nat Med